Tharimmune, Inc. is a biotechnology company focused on developing innovative therapies to address autoimmune diseases and other immune system-related disorders
The company leverages advanced technologies and scientific research to create targeted treatments that aim to modulate immune responses, improving patient outcomes and quality of life. Tharimmune's pipeline includes several therapeutic candidates in various stages of development, reflecting its commitment to advancing the understanding and treatment of complex immunological conditions. Through collaborations and a dedicated approach to research and development, Tharimmune aspires to make significant contributions to the field of immunotherapy.
Tharimmune, Inc. (NASDAQTHAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver Disease (AASLD) meeting. Here's what you need to know.
Tharimmune, Inc. (NASDAQTHAR) shares are moving higher on Wednesday after the company announced it received overall positive feedback from the European Medicines Agency (EMA) on its TH104 clinical program.
Tharimmune shares are trading lower by 30% during Monday's session. The company late Friday announced it had entered into an "at the market" offering agreement.
Tharimmune achieves success in Phase 1 trial for TH104, a buccal film with nalmefene. Encouraging safety profile and potential for liver-related conditions.
